Rankings
▼
Calendar
JAZZ Q4 2021 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena
JAZZ
Jazz Pharmaceuticals plc
$12B
Q4 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$897M
+34.7% YoY
Gross Profit
$761M
84.8% margin
Operating Income
$49M
5.5% margin
Net Income
-$35M
-3.9% margin
EPS (Diluted)
$-0.57
QoQ Revenue Growth
+7.0%
Cash Flow
Operating Cash Flow
$178M
Free Cash Flow
$168M
Stock-Based Comp.
$53M
Balance Sheet
Total Assets
$12.3B
Total Liabilities
$8.3B
Stockholders' Equity
$4.0B
Cash & Equivalents
$591M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$897M
$666M
+34.7%
Gross Profit
$761M
$615M
+23.6%
Operating Income
$49M
$173M
-71.5%
Net Income
-$35M
$133M
-126.5%
Revenue Segments
Xyrem
$289M
33%
Epidiolex/Epidyolex
$194M
22%
Xywav
$183M
21%
Rylaze/Enrylaze
$65M
7%
Zepzelca
$65M
7%
Defitelio/Defibrotide
$43M
5%
Vyxeos
$35M
4%
Sativex
$5M
1%
Other Products
$1M
0%
Geographic Segments
UNITED STATES
$824M
92%
Europe
$65M
7%
Other Countries
$8M
1%
← FY 2021
All Quarters
Q1 2022 →